Vesugen Dosage Chart
Vesugen is dosed at 500 mcg–2 mg daily via subcutaneous injection in educational protocols. A Lys-Glu-Asp reconstituted with bacteriostatic water yields about 6.67 mg/mL. This information is for research and educational use only.
- Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
- Typical daily range: 500–2000 mcg once daily (gradual titration).
- Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Vesugen (Lys-Glu-Asp, also known as KED) is a tripeptide bioregulator synthesized at the Saint Petersburg Institute of Bioregulation and Gerontology[1]. Research suggests it may support vascular endothelial cell proliferation through epigenetic regulation of Ki-67 gene expression[2]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~6.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 500 mcg (0.5 mg) | 7.5 units (0.075 mL) |
| Week 2 | 1000 mcg (1.0 mg) | 15 units (0.15 mL) |
| Week 3 | 1500 mcg (1.5 mg) | 22.5 units (0.225 mL) |
| Weeks 4–8+ | 1500–2000 mcg (1.5–2.0 mg) | 22.5–30 units (0.225–0.30 mL) |
Frequency: Inject once daily subcutaneously. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability. Note that Week 1 dosing falls at 7.5 units; a 50-unit syringe with 0.5-unit graduations improves accuracy.
Reconstitution Steps
Plan based on an 8–16 week daily protocol with gradual titration (targeting ~1500 mcg/day maintenance).
- Peptide Vials (Vesugen, 20 mg each):
- 8 weeks (~84 mg total) ≈ 5 vials
- 12 weeks (~126 mg total) ≈ 7 vials
- 16 weeks (~168 mg total) ≈ 9 vials
- Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
- Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (5 vials): 15 mL → 2 × 10 mL bottles
- 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
- 16 weeks (9 vials): 27 mL → 3 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Protocol Overview
Concise summary of the once-daily regimen.
- Goal: Support vascular endothelial function and cellular renewal over time[2].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 500–2000 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Dosing Protocol
Suggested daily titration approach.
- Start: 500 mcg daily; increase by ~500 mcg weekly as tolerated.
- Target: 1500–2000 mcg daily by Weeks 3–8+.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality[10].
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation[12].
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
Vesugen (KED) is a tripeptide derived from amino acids associated with vascular wall proteins[1]. Research indicates it may support vascular endothelial cell proliferation by modulating the expression of Ki-67, a protein closely associated with cell division[2]. The peptide is hypothesized to interact with promoter regions of the Ki-67 gene, potentially influencing epigenetic regulation[3]. Additional studies suggest Vesugen may normalize endothelin-1 expression and increase sirtuin-1 (SIRT-1) expression in vascular endothelial cells[4].
Observations from preclinical and cell culture research.
- May support vascular endothelial cell proliferation and renewal through Ki-67 gene regulation[2][3].
- Research suggests potential neuroprotective properties; oral application improved memory and attention in elderly individuals with functional CNS disorders[5].
- May restore synaptic plasticity in in vitro models of Alzheimer’s disease[6].
- Generally well tolerated in reported studies; occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.
Complementary strategies for best outcomes.
- Pair with a balanced, heart-healthy diet rich in antioxidants and omega-3 fatty acids.
- Combine regular cardiovascular exercise to reinforce vascular adaptations.
- Prioritize sleep and stress management to support recovery and cellular renewal.
General subcutaneous guidance from clinical best-practice resources[11].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[11][12].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[11].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[12].
Recommended Source
We recommend Pure Lab Peptides for high-purity Vesugen (20 mg).
Why Pure Lab Peptides?
- High-purity, third-party-tested lots with batch COAs.
- Consistent, ISO-aligned handling and documentation.
- Reliable fulfillment to maintain cold-chain integrity.
Important Note
This content is for educational purposes only and is not medical advice.
References
-
Bull Exp Biol Med (2016)— Short Peptides Regulate Gene Expression (Khavinson et al.)
-
Adv Gerontol (2014)— Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging
-
Molecules (2021)— Peptide Regulation of Gene Expression: A Systematic Review (MDPI)
-
Adv Gerontol (2016)— Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis
-
Bull Exp Biol Med (2021)— Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer’s Disease
-
Bull Exp Biol Med (2017)— Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer’s Disease
-
Int J Mol Sci (2022)— Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease
-
Pharmaceuticals (2021)— Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer’s Disease
-
DailyMed— Bacteriostatic Water injection, solution (FDA labeling)
-
PMC (2024)— Practical advice in the development of a lyophilized protein drug product
-
MedlinePlus— Subcutaneous (SQ) injections: technique and site guidance
-
NCBI Bookshelf— Best practices for injection (WHO guidelines)
-
CDC— Vaccine administration: subcutaneous injection technique
-
Biogerontology (2010)— Peptide bioregulation of aging: Results and prospects (Anisimov & Khavinson)
-
Stem Cell Rev Rep (2020)— Peptide Regulation of Cell Differentiation
-
Pure Lab Peptides— Vesugen (20 mg) product page (quality and batch documentation)